Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from the sovleplenib ESLIM-01 Phase III trial, as well as several investigator-initiated studies of compounds ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback